CA3235733A1 - Tadalafil oral suspension - Google Patents
Tadalafil oral suspension Download PDFInfo
- Publication number
- CA3235733A1 CA3235733A1 CA3235733A CA3235733A CA3235733A1 CA 3235733 A1 CA3235733 A1 CA 3235733A1 CA 3235733 A CA3235733 A CA 3235733A CA 3235733 A CA3235733 A CA 3235733A CA 3235733 A1 CA3235733 A1 CA 3235733A1
- Authority
- CA
- Canada
- Prior art keywords
- comprised
- preferably comprised
- still
- tadalafil
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382964 | 2021-10-25 | ||
| EP21382964.1 | 2021-10-25 | ||
| PCT/EP2022/079659 WO2023072872A1 (en) | 2021-10-25 | 2022-10-24 | Tadalafil oral suspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3235733A1 true CA3235733A1 (en) | 2023-05-04 |
Family
ID=78528864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3235733A Pending CA3235733A1 (en) | 2021-10-25 | 2022-10-24 | Tadalafil oral suspension |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250241911A1 (enExample) |
| EP (1) | EP4422599B1 (enExample) |
| JP (1) | JP2024541013A (enExample) |
| CN (1) | CN118284408A (enExample) |
| AU (1) | AU2022374786A1 (enExample) |
| CA (1) | CA3235733A1 (enExample) |
| DK (1) | DK4422599T3 (enExample) |
| FI (1) | FI4422599T3 (enExample) |
| MX (1) | MX2024005048A (enExample) |
| WO (1) | WO2023072872A1 (enExample) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7018658B2 (en) | 2002-11-14 | 2006-03-28 | Synthon Bv | Pharmaceutical pellets comprising tamsulosin |
| US20060147531A1 (en) | 2003-07-01 | 2006-07-06 | Mojca Segula | Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate |
| SI21637A (sl) | 2003-12-23 | 2005-06-30 | LEK farmacevtska dru�ba d.d. | Farmacevtska oblika z nadzorovanim sproščanjem |
| KR20070021806A (ko) | 2005-08-19 | 2007-02-23 | (주)아모레퍼시픽 | α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법 |
| KR100745515B1 (ko) | 2006-04-10 | 2007-08-02 | 주식회사 대웅제약 | 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법 |
| KR20160021095A (ko) | 2013-06-21 | 2016-02-24 | 욱크하르트 리미티드 | 탐술로신 또는 이의 염의 약학 조성물 |
| CZ2015225A3 (cs) | 2015-03-30 | 2016-10-12 | Zentiva, K.S. | Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI |
| EP3498264B1 (en) * | 2016-08-12 | 2023-11-08 | Hanmi Pharm. Co., Ltd. | Pharmaceutical preparation for oral administration with controlled dissolution rate, the preparation comprising tamsulosin hydrochloride-containing sustained-release pellets |
| EP3576741A1 (en) | 2017-02-02 | 2019-12-11 | Dukebox SP. Z O.O. | A method of manufacturing a suspension of nanoparticles of tadalafil or sildenafil citrate |
| EP3473245A1 (en) | 2017-10-20 | 2019-04-24 | Veru Inc. | Controlled release oral tamsulosin hydrochloride |
| WO2020039263A2 (en) | 2018-08-18 | 2020-02-27 | Ftf Pharma Private Limited | Pharmaceutical suspension for oral dosage |
-
2022
- 2022-10-24 US US18/703,099 patent/US20250241911A1/en active Pending
- 2022-10-24 MX MX2024005048A patent/MX2024005048A/es unknown
- 2022-10-24 DK DK22809383.7T patent/DK4422599T3/da active
- 2022-10-24 CN CN202280077312.5A patent/CN118284408A/zh active Pending
- 2022-10-24 CA CA3235733A patent/CA3235733A1/en active Pending
- 2022-10-24 AU AU2022374786A patent/AU2022374786A1/en active Pending
- 2022-10-24 EP EP22809383.7A patent/EP4422599B1/en active Active
- 2022-10-24 WO PCT/EP2022/079659 patent/WO2023072872A1/en not_active Ceased
- 2022-10-24 FI FIEP22809383.7T patent/FI4422599T3/fi active
- 2022-10-24 JP JP2024524693A patent/JP2024541013A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250241911A1 (en) | 2025-07-31 |
| MX2024005048A (es) | 2024-05-10 |
| EP4422599A1 (en) | 2024-09-04 |
| DK4422599T3 (da) | 2026-03-30 |
| FI4422599T3 (fi) | 2026-03-25 |
| CN118284408A (zh) | 2024-07-02 |
| EP4422599B1 (en) | 2026-01-28 |
| JP2024541013A (ja) | 2024-11-06 |
| AU2022374786A1 (en) | 2024-06-13 |
| WO2023072872A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2567075C (en) | Pharmaceutical suspension composition | |
| BRPI0212922B1 (pt) | Composição farmacêutica na forma de um comprimido dispersável compreendendo uma dispersão sólida de 40-o-(2-hidroxietil)-rapamicina, seu processo de preparação e uso da dita composição | |
| TW200803831A (en) | Solid pharmaceutical compositions containing pregabalin | |
| CA2992404C (en) | Pharmaceutical composition containing celecoxib and tramadol | |
| CN104736142A (zh) | 阿哌沙班液体制剂 | |
| US20020147232A1 (en) | Pharmaceutical compositions comprising desglymidodrine as an active drug substance | |
| JP2021185139A (ja) | ミラベグロンまたはその塩を含む放出調節用薬剤学的組成物 | |
| CA2393737A1 (en) | Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption | |
| US20080064713A1 (en) | Dry Syrup Containing Loratadine | |
| US20040052847A1 (en) | Oral dosage forms of water insoluble drugs and methods of making the same | |
| EP4422599B1 (en) | Tadalafil oral suspension | |
| EP3968955B1 (en) | Pharmaceutical oral liquid solution of ivacaftor | |
| JP4995099B2 (ja) | 非可塑性薬の矯味システム | |
| CA3164495C (en) | LIQUID COMPOSITION CONTAINING IBUPROFEN AND PHENYLEPHRINE | |
| EP2138173A1 (en) | Pharmaceutical compositions comprising aminoadamantane derivatives | |
| CA2802142C (en) | Ciprofloxacin dry syrup composition | |
| Namdev | Formulation and Evaluation of Mouth Dissolving Tablets of Metoprolol Tartrate | |
| HK40077494B (en) | Liquid composition comprising ibuprofen and phenylephrine | |
| HK40077494A (en) | Liquid composition comprising ibuprofen and phenylephrine | |
| CN119546305A (zh) | 泛raf激酶抑制剂的口服液体悬浮液 | |
| Patel | Formulation, Development and Evaluation of Expectorant Extended Release Tablet | |
| Rakkanka | 1. A novel self-sealing chewable sustained release tablet of acetaminophen, 2. Development and evaluation of novel itraconazole oral formulations, 3. A novel zero order release matrix tablet | |
| HK1198466A1 (en) | Prasugrel-containing immediate release stable oral pharmaceutical compositions | |
| HK1198466B (en) | Prasugrel-containing immediate release stable oral pharmaceutical compositions | |
| HK1172252A (en) | Pharmaceutical suspension composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241018 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241018 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241018 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251017 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251017 |